Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2015 Jun 25;125(26):3974-5.
doi: 10.1182/blood-2015-05-640672.

Syk and tired of current chronic GVHD therapies

Daniel H Fowler  1 , Steven Z Pavletic  1
Affiliations
Comment

Syk and tired of current chronic GVHD therapies

Daniel H Fowler et al. Blood. .

Abstract

In this issue of Blood, Flynn et al1 provide key data that lend further support to the development of clinical trials of spleen tyrosine kinase (Syk) inhibition for more effective chronic graft-versus-host disease (cGVHD) treatment.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests. The opinions expressed herein are those of the authors and do not represent the official position of the National Institutes of Health or the United States Government.

Figures

None
Flynn et al have demonstrated that Syk signaling within allogeneic B cells contributes to murine cGVHD and can be successfully targeted with TKI therapy. The effect was most dramatic in a model of bronchiolitis obliterans, which is a devastating complication of allogeneic hematopoietic cell transplantation (HCT). Because Syk inhibition holds promise for the treatment of multiple hematologic malignancies, targeting this pathway represents an exciting new intervention to improve both the safety and the efficacy of allogeneic HCT. Professional illustration by Patrick Lane, ScEYEnce Studios.
See this image and copyright information in PMC

Comment on

  • Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease.
    Flynn R, Allen JL, Luznik L, MacDonald KP, Paz K, Alexander KA, Vulic A, Du J, Panoskaltsis-Mortari A, Taylor PA, Poe JC, Serody JS, Murphy WJ, Hill GR, Maillard I, Koreth J, Cutler CS, Soiffer RJ, Antin JH, Ritz J, Chao NJ, Clynes RA, Sarantopoulos S, Blazar BR. Flynn R, et al. Blood. 2015 Jun 25;125(26):4085-94. doi: 10.1182/blood-2014-08-595470. Epub 2015 Apr 7. Blood. 2015. PMID: 25852057 Free PMC article.

References

    1. Flynn R, Allen JL, Luznik L, et al. Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood. 2015 125(26):4085-4094. - PMC - PubMed
    1. Leonhardt F, Zirlik K, Buchner M, et al. Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels. Leukemia. 2012;26(7):1617–1629. - PubMed
    1. Le Huu D, Kimura H, Date M, et al. Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease. J Dermatol Sci. 2014;74(3):214–221. - PubMed
    1. Pavletic SZ, Vogelsang GB, Lee SJ. 2014 National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: preface to the series. Biol Blood Marrow Transplant. 2015;21(3):387–388. - PubMed
    1. Lucas MC, Tan SL. Small-molecule inhibitors of spleen tyrosine kinase as therapeutic agents for immune disorders: will promise meet expectations? Future Med Chem. 2014;6(16):1811–1827. - PubMed

MeSH terms

Substances